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ABSTRACT
ATTENUATION OF ANTAGONIST-INDUCED IMPAIRMENT
IN DOPAMINE RECEPTOR ONTOGENY
BY L-PROLYL-L-LEUCYL-GLYCINAMIDE
by
Mohamad Iqbal Saleh, M.D.
It has been shown by others that the prenatal treatment
of rats with haloperidol, a dopamine D2 receptor antagonist,
leads to a permanent reduction in the number of striatal
dopamine D2 receptors in adulthood.
Conversely, postnatal
treatment of lactating dams with haloperidol from birth for
21 days, leads to an increase in the number of striatal
dopamine D2 receptors in the litters, when assessed as
adults.
The present study was undertaken in order to
determine whether chronic, long-term postnatal challenge of
rat pups per se, with specific dopamine D1 and D2 receptor
antagonists, would modify the ontogeny of the respective
receptor types.
Since the neuropeptide
L-prolyl-L-leucyl-glycinamide (PLG) attenuates the effect of
haloperidol on dopamine D2 receptors in adult rats, it was of
interest to determine whether PLG would modulate
antagonist-induced alterations in the ontogeny of striatal
dopamine D1 and D2 receptors. Half of the rats were treated
daily for 32 cjlays from birth with SCH-23390 (0.30 mg/kg/d
i.p.), a selective dopamine D1 antagonist; or spiroperidol
(1.0 mg/kg/d i.p.), a selective dopamine D2 antagonist; or
both SCH-23390 and spiroperidol; or saline. The other half
of the litters were treated with PLG (1.0 mg/kg/d, i.p.), in
combination with the other treatments. Animals were
decapitated at 5,8, and 12 weeks from birth for neurochemical
analysis of the striatum. Chronic SCH-23390 treatment
produced a 70-80% decrease in the binding of [3H] SCH-23390
(300 pM) to striatal homogenates.
The alteration at 5 weeks
was associated with a 78% decrease in the Bmax for [3H]
SCH-23390 binding, and no change in the K^. Similarly, at 5,
8, and 12 weeks, chronic spiroperidol treatment reduced the
binding of [3H] spiroperidol (300pM) to striatal homogenates
by 70-80%. The alteration at 5 weeks was associated with a
74% decrease in the Bmax for [3H] spiroperidol binding, and
no change in K q . Furthermore, PLG attenuated these
respective changes in dopamine D1 and D2 binding, when
assessed at 5 and 8 weeks.
These findings demonstrate that
the postnatal period is a sensitive and critical time in the
development of striatal dopamine Dl and D2 receptors and that
PLG is able to attenuate the alterations in ontogeny that are
produced by dopamine Dl and D2 receptor antagonists.
iii
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Chapter I
Introduction

Anatomical Review:
Carlsson et al.

(1958) made their important suggestion

that dopamine is not only an intermediate precursor of
norepinephrine synthesis, but is also a unique monoamine with
specific properties-and functions in the central nervous
system (CNS).

Following this suggestion, Ahlstrtim and Fuxe

(1964), using a histochemical formaldehyde condensation
method, mapped the central monoaminergic systems in great
detail. It was found that

dopaminergic cell bodies are

located mainly in three major areas:
1.

Zona compacta of the substantia nigra (Ag )

2.

Ventral tegmental area (A10)

3.

Arcuate nucleus and the ventral periventricular
hypothalamic nucleus (A1 2 )

From the dopamine cells in A g , the nigrostriatal
dopamine system (dorsal component of the mesostriatal
dopamine system) arises, and terminates in the caudate
I

nucleus, putamen, globus

pallidus and subthalamic nucleus.

From the dopamine cells in A^ q , the mesolimbic dopamine
system (ventral component of the mesostriatal dopamine
system) arises, and terminates in the nucleus accumbens,
olfactory tubercle, nucleus interstitialis stria terminalis,
hypothalamus, preoptic area, prefrontal cortex, cingulate

cortex, hippocampus, amygdala, and midbrain; and from the
dopamine cells in A 12, the tuberoinfundibular and
tuberohypophyseal dopamine system arises and terminates in
the median eminence, infundibular stalk, and intermediate and
neural lobes of the pituitary (Beckstead et al., 1979; and
Nauta et al., 1978).
Proposed Function Of Dopamine Systems:
*

As of now, two major neurological functions can be
directly related to dopamine systems:
1.

Behavior:

Various behaviors can be modulated by

dopaminergic transmission. The nigrostriatal pathway
is associated with motor behavior, while the mesolimbic,
mesocortical pathways are associated with mood behavior,
1.e., stereotyped behavior (Creese, 1973), self
stimulation behavior (Phillips and Libiger, 1973),
conditioned avoidance responding behavior (Ungerstedt,
1971), stimulus control behavior (Ho and Huang, 1975),
and feeding and drinking behavior (Ungerstedt, 1971).
2.

Neuroendocrine function (tuberohypophyseal

dopaminergic system):

Neuroendocrine function was

recognized from studies on the effect of dopamine on the
hypothalamus, gonadal steroids and prolactin secretion
(MacLeod 1976).
Dopamine Receptors:
The properties of dopamine receptors were first
characterized in 1975 following their identification by

receptor-binding techniques utilizing [3H]-butyrophenones,
the potent anti-psychotic drugs used in the treatment of
schizophrenia (Snyder et al., 1975; Seeman et al., 1975).
These receptors were termed dopamine D2 receptors, since
another type of dopamine receptor had been identified years
earlier, even though its functional properties were unknown
(Billard et al., 1974).
*

Later, Cools and Van Rossum (1976) modified the concept
of multiple dopamine receptors.

Kebabian and Caine (1978)

followed up on that and classified dopamine receptors into Dj
and □2 receptors, where dopamine

is the receptor that is

linked to dopamine-sensitive adenylate cyclase, and the
dopamine D2

receptor represents the group that is not linked

to dopamine sensitive adenylate cyclase.

However, this

classification is not satisfactory since:

1— Adenylate

cyclase does not exist in all dopamine receptor- containing
tissue (i.e. pituitary)

(Ahn et al., 1979).

2— It is not

practically possible to biochemically separate the amount of
dopamine receptors linked and nonlinked to adenylate cyclase
*

(Kebabian and Caine, 1979).

3— There is no clear

relationship between the effect of the dopamine agonists and
antagonists on behavior and their effect on adenylate cyclase
(Mcermed and Miller, 1979).
The gradual discovery of highly specific dopamine
receptor agonists and antagonists made it possible to
characterize dopamine D 2 receptors (Creese et al., 1977;

Leysen et al., 1978, Laduron and Leysen, 1979) and dopamine
Dj_ receptors (Iorio et al., 1981; Hyttel, 1983; Iorio et al.,
1983).

Also, it was then possible to classify dopamine

and 2 receptors on the basis of specific binding to selective
agonists and antagonists.
Selective Dopamine Do and
Creese et al.

Studies:

(1977) and Laduron and Leysen (1979),

using radioligand binding studies with [3H] spiroperidol, a
selective dopamine D2 receptor antagonist, labeled dopamine
d2 receptors in the central nervous system.

Klemm et al.

(1979) utilized autoradiography with [3H] spiroperidol and
localized high densities of dopamine 2 receptors in the
neostriatum (caudate-putamen), nucleus accumbens, olfactory
tubercle, and also in the substantia nigra.
The dopamine

receptors have been studied using

oxanthenes such as cis-[3H] piflupentixol (Hyttel, 1978) and
cis-(Z)-[3H] pifluthixol (Hyttel, 1981).

However, these

radioligands also label dopamine D2 receptors (Hyttel and
Arnt, 1980). SCH-23390[(R)-(+)-7-Chloro-8-hydroxy-3-methyl*

1-phenyl-2,3,4,5-tetrahydro-l-H-3-benzazepine] is a new
benzazepine which is a selective

antagonist (Iorio et al.,

1981; Hyttel, 1983) and shows a potent blockade of the
dopamine-stimulated adenylate cyclase (Onali et al, 1984).
Radioligand studies have shown that [3H]SCH-23390 labels and
binds specifically and with high affinity to dopamine
receptors in the neostriatum (Schulz et al., 1985).

Dopamine Receptor Distribution:
The distribution of dopamine

and 2 receptors in the

brain areas of different species was studied by Hyttel et al.
(1978),

It was found that there are 2-6 times more dopamine

Di receptor binding sites than dopamine ^2 receptor binding
sites in rat corpus striatum; the same ratio is found in the
mouse striatum.

In areas of the brain rich in dopamine

receptors, the number of dopamine Di receptor binding sites
is greater than the number of dopamine D2 receptor binding
sites, but in different ratios (Hyttel, 1978; Hyttel and
Arnt, 1986).
Today even though there have been intensive studies
performed on the function of dopamine Di and ^2 receptors,
there is still no clear picture of how dopamine Di and D 2
receptors and other neuroreceptors interact in the brain to
carry out their function.
Dopamine Di , P2 Receptor Function And Interaction:
Marked correlation exists between the ability of
neuroleptic drugs to displace [3H] spiroperidol from specific
binding sites on dopamine D 2 receptors and their
anti-psychotic activity (Creese et al., 1979; Seeman, 1980).
Therefore, the action of neuroleptics on dopamine D 2 receptor
sites can explain some the functions of dopamine receptor
activation.
However, it seems that dopamine D 2 receptors do not
function independently of dopamine Di receptors, and several

studies have provided evidence for dopamine D i -D2 receptor
interaction.

For example, SKF 38393, a dopamine

receptor

agonist, stimulates the release of cAMP from superfused
striatal tissue slices; this stimulation is antagonized by LY
141865, a selective dopamine D2 receptor agonist.
Furthermore,

(-)sulpiride, a dopamine D2 receptor antagonist,

prevents the effect of LY 141865 (Stool and Kebabian, 1981).
Low doses of spiroperidol can induce abnormal perioral
movements in rats; these abnormal movements can be
potentiated by SKF 38393, the dopamine

agonist

(Rosengarten et al., 1983). It was also found that
intravenous administration of SKF 38393 and RU 24926, a
dopamine D2 agonist, produced synergestic effects on the
expression of stereotypic behavior and on the firing rate of
basal ganglia neurons in rats. Furthermore, simultaneous
stimulation of both dopamine

and D2 receptors produces

greater firing rate and behavioral changes similar to those
produced by non-selective dopamine receptor agonists (i.e.
apomorphine; Walters et al., 1987).

In vitro studies have

*

also shown that haloperidol, at concentrations which appear
to be selective for dopamine D2 receptor blockade, increases
the release of [3H] acetylcholine (ACh) from superfused
striatal tissue slices (Starke et al., 1983); SCH-23390, the
dopamine
release.

antagonist, is capable of antagonizing [3H] ACh
These findings suggest that dopamine

and D2

receptor interaction may be an important determinant of
maintaining balanced behavioral activities.
6-Hvdroxvdopamine and Dopamine Receptors:
6-Hydroxydopamine, a relatively selective neurotoxin for
catecholaminergic neurons, produces destruction of central
noradrenergic and dopaminergic fibers after
intraeerebroventricular administration to rats (Kostrzewa and
*

Jacobowitz, 1974).

To diminish noradrenergic fiber

destruction, desmethylimpiramine (DMX), an inhibitor of
norepinephrine reuptake, may be used as a pretreatment
(Breese and Traylor, 1972).

Also, by co-administering

pargyline, a monoamine oxidase inhibitor, the destructive
action of 6-hydroxydopamine on dopaminergic fibers can be
potentiated (Breese and Traylor, 1970).
The destruction of dopamine nigrostriatal fibers is
associated with specific motor behavioral dysfunctions, i.e.,
aphagia, adipsia and akinesia (Ungerstedt, 1971; Marshall et
al,, 1974) and a proliferation of dopamine D 2 receptors
(Breese et al., 1984).
These alterations may appear in Parkinson's disease,
where the number and function of dopamine cells is reduced in
the substantia nigra.

Also, after chronic anti-psychotic

agents, such as haloperidol, the striatal dopamine receptors
are greatly increased in number, and motor behavior
dysfunctions are observed (Tarsy and Baldessarini, 1974).

Haloperidol and Dopamine Receptors:
Haloperidol is an anti-psychotic drug that is used
chronically in man.

Animal studies have shown that chronic

injection of haloperidol causes up-regulation
(supersensitivity) of striatal dopamine D2 receptors in adult
rats (Muller and Seeman, 1977; Chiu et al,, 1981) and in
neonatal rats (Rosengarten and Friedhoff, 1979).
Furthermore, haloperidol causes a down-regulation (decrease
in number) of striatal dopamine D2 receptors in neonatal rats
following prenatal administration (Rosengarten and Friedhoff,
1979).

However, haloperidol is a non-selective dopamine d 2

receptor antagonist (70% D2) (Murrin, 1982); new agents have
been found which are more specific antagonists.
Dopamine and Dopamine Receptor Ontoaenvi
A — Dopaminergic Input Prior to Birth
Three major dramatic changes in the dopaminergic input
to rat striatum occur prior to birth and for the 8 week
period after birth:
1)

Tyrosine hydroxylase activity increases (Coyle et
i

al., 1976).
2)

There is a gradual increase in dopamine

concentration and dopamine uptake (Coyle et al., 1976).
The rat striatum contains 12-24% of the adult (i.e., 90
days old) level of dopamine at birth.

The dopamine

content increases slowly until it reaches adult levels
by postnatal day 60, and then remains constant through

adulthood and senescence (up to 20 months of age).
3)

There is a rapid increase in the dopamine receptor

number up to adult levels by postnatal day 30-35 (Giorgi
et al., 1987;
B— Dopamine

Murrin, 1982).

Receptor Ontogeny:

Giorgi et al.

(1987) found that the density of dopamine

receptors labeled with [3H] SCH-23390 in rat striatum was
*

only 9% of the adult value at birth, and increased rapidly,
continuing

until day 35, when dopamine

receptor density

attained maximum values and then decreased significantly with
age; i.e. the B ^ x for dopamine D;l binding to the striatum at
35 days was 1.75 pmol/mg protein versus 1.2 at 90 days, and
0.89 at 270 days.
C— Dopamine_D2 Receptor Ontogeny:
Murrin (1982) studied the ontogeny of dopamine D 2
receptors using in vivo [3H] spiroperidol binding studies in
5, 15 and 30 day old rat pups.

It was found that dopamine D2

receptors doubled in number between day 5 and day 15, and
then gradually increased in number reaching adult levels by
day 30.

This observation is similar to the in vitro study on

dopamine D2 receptor ontogeny by Pardo and Creese (1977).
Impairment of Dopamine Receptor Ontogeny:
The normal ontogeny of dopamine D2 receptors can be
impaired by prenatal treatment with dopamine receptor
antagonists.

Rosengarten and Friedhoff (1979) showed that

when the neuroleptic haloperidol is administered to pregnant

10
dams, a persistent decrease in the number of dopamine D2
receptors occurs in the offspring.

Later, it was found that

days 15-18 of the gestational period was the critical time
for that effect (Rosengarten et al., 1983).

This finding was

confirmed by Miller and Friedhoff (1986).
It has also been shown that treatment of nursing dams
with haloperidol for 21 days after giving birth results in a
*

40% increase in the number

of striatal dopamine D2 receptors

in the littermates two weeks after the last dose of
haloperidol has been administered to the dam (Rosengarten and
Friedhoff, 1979).

other studies have shown that treatment of

neonatal rats with penfluridol, a neuroleptic similar to
haloperidol, on alternate days during the first postnatal
week does not affect the development of striatal dopamine D2
receptors, although there is a supersensitive response of
these rats to the dopamine receptor agonist, apomorphine, as
adults (Coyle et al., 1981).
Until now, there have been no studies to determine the
striatal dopamine

and D2 receptor response to highly

4

selective dopamine

and D2 antagonists administered either

prenatally or postnatally.

This type of specific experiment

is important to gain more knowledge on the ontogeny of
dopamine receptors and their response to chronic blockade by
specific antagonists.

11
Dopamine Receptors Ana L-Prolvl-L-Leucvl-Glvcinaroide fPLGl:
It is accepted that the hypothalamic tissue of many
species, including man, contains a substance that inhibits
the release of melanocyte stimulating hormone (MSH) from the
pituitary gland (Kastin and Schally, 1966); this
neurohormonal substance is called melanocyte stimulating
hormone release inhibiting factor (MIF).

Nair et al.(1971a)

determined the structure of MIF to be L-prolyl-L-leucylglycinamide (PLG)

and synthesized

this substance, which had

biological activities similar to those of naturally-occurring
bovine MIF.

It was also found that PLG has a short

biological half-life, approximately 9 minutes (Redding et
al., 1973).

Several studies have demonstrated that PLG

produces a wide variety of behavioral and neurochemical
actions in the absence of the pituitary gland.

The search

for a better and safer treatment for behavior dysfunctions
(i.e., psychoses and Parkinson's disease) has brought about
the promising role of PLG in specifically modulating
dopaminergic processes in the mammalian brain.

It was

found

*

that PLG potentiates the effects of dihydroxyphenylalanine
(L-dopa) on motor performance in both intact and
hypophysectomized mice (Plotnikoff.1971) and in humans
(Barbeau, 1975). PLG is also devoid of the adverse
neurological side-effects of the L-dopa treatment (Barbeau et
al., 1978). clinical studies indicated that PLG temporarily,
but significantly, reduced the intensity of dyskinetic

12
symptoms associated with chronic anti-psychotic therapy
(Ehrensing, 1974; Kastin et al., 1977).
Later, Chiu et al.

(1981) showed that PLG was able to

attenuate dopamine receptor supersensitivity caused by
chronic administration of haloperidol in rats.

Bhargava

(1981a) also observed that PLG was able to inhibit the
development of tolerance to the cataleptic and hypothermic
effect of haloperidol in the rat.

Chiu et al.

(1981) also

showed that PLG is able to block the behavioral
supersensitivity of dopamine receptors induced by
haloperidol.
Other studies have also demonstrated important findings.
Bhargava (1981) found that PLG and its cyclic analog, cyclo
(Leu-Gly), are able to block the development of analgesic
tolerance and dopamine receptor supersensitivity induced by
chronic morphine treatment.

In addition,

Ritzman et al.

(1982) found that cyclo (Leu-Gly), when injected into rats
prior to chronic exposure to morphine, inhibited
morphine-induced increases in behavioral responses to
dopamine agonists in addition to the inhibition of some signs
of physical dependence.
Further studies were done to determine PLG binding sites
in human brain.

It was found that [3H] PLG bound to membrane

homogenates with high affinity in a saturable manner.
Substantia nigra had the highest level of specific [3H] PLG
binding followed by striatum and hypothalamus.

It was

concluded that specific PLG binding sites do exist in the
human brain and these binding sites may be strategically
localized to be able to modulate the changes in the number of
dopamine receptors (Chiu et al., 1980).

It has also been

found that PLG has distinct binding sites in the rat brain,
with the highest density in substantia nigra and striatum.
PLG also selectively increases the affinity of the specific
*

binding of the dopamine agonist [3H] apomorphine to dopamine
receptors and does not compete for dopamine/neuroleptic
receptor binding (Chiu et al., 1981).
It can be concluded that PLG is a neuropeptide that
interacts with specific binding sites in the brain and
carries out specific functions related to modifying the
dopamine system; the mechanism is not yet clear.
Katlonale:
This study was undertaken to determine whether postnatal
challenge of rat pups with specific dopamine

and D 2

receptor antagonists would modify the ontogeny of the
respective receptor populations in the striatum and to
determine whether PLG was capable of modulating the changes
in the ontogeny of these dopamine receptors.
It would appear that chronic blockade of dopamine
receptors may serve as a model by which many neurological and
behavioral dysfunctions can be observed.

For example,

schizophrenia is conventionally treated with dopamine d 2
antagonists.

However, protracted treatment with these agents

may lead to tardive dyskenesia in humans and to dopamine D2
supersensitivity (increase in number) in rats (Chiu, 1981);
prolonged treatment of Parkinson's Disease with dopamine
agonists leads to dopamine receptor desensitization and
worsens the disease manifestations (Rinne et al., 1979).
Dopamine desensitization mimics down-regulation of dopamine
receptors (decrease in number).

In rats, dopamine receptor

down-regulation may be caused by prenatal treatment with
dopamine D2 antagonists (Rosengarten and Friedhoff, 1979}.
Acute and chronic cocaine administration in rats causes
dopamine receptor supersensitivity (Taylor et al., 1979),
which may be the reason behind severe cravings for cocaine
and the resulting abuse of cocaine in humans (Dackis and
Harks, 1984). A better understanding of these processes could
be of value in promoting the development of a viable
treatment for these types of dysfunctions in man. For
example, PLG may be of use in antagonizing the dependence and
dysfunctions caused by drugs of abuse. PLG may also be of
benefit in combination with anti-psychotic drugs, in order to
prevent the development of tardive dyskinesia. Similar uses
of PLG are suggested for preventing L-dopa-induced side
effects in Parkinsonian patients.
In summary, the present study was undertaken to study
dopamine receptor ontogeny under chronic blockade with
specific antagonists and to test the ability of PLG to
attenuate any abnormal changes in that ontogeny.
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chapter II
Material and Method

This project can be divided into two experiments. The
first experiment was conducted to determine the effect of
chronic blockade with specific antagonists on the ontogeny of
dopamine

and D 2 receptors and to test the ability of plg

to attenuate receptor changes produced by the antagonists.
The second experiment can be divided into two studies:
The first study was undertaken to test the long-term effect
of specific neonatal blockade on dopamine

and D2

receptors. Rats were treated with specific dopamine
antagonists for 32 days, then studied at 12 weeks.

or D2
The

second study was undertaken to determine adult dopamine
and D2 receptor response to specific blockade; 12 week old
rats were treated with specific antagonists for 17 days, then
decapitated.

The same rats had been treated postnatally for

32 days from the day of birth.
Animals and Treatment:
Timed pregnant Sprague Dawley albino rats were obtained
from Charles River Labs (Reserach Triangle, NC ) .

Animals

were housed individually in plastic cages and maintained
under standard laboratory conditions (ad libitum access to
food and water, temperature of 22±1 °C, and 12 hour
light-dark cycle, on at 0700 hour).

Starting at birth, all

neonates were treated once a day for 32 successive days by
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intraperitoneal injection (i.p.) with one of the following
regimens:

(a) saline (0.9%), the SCH-23390.HC1 solvent, plus

saline containing tartaric acid (0.5%), the spiroperidol
solvent, and acetic acid (0.5 m M ) , the PLG solvent,

(b)

SCH-23390.HCl (0.30 mg/kg, free base; Research Biochemicals,
Inc., Natick, HA) in saline (0.9%) plus saline-tartaric
acid/acetic acid,

(c) spiroperidol (1.0 mg/kg i.p., Research
V

Biochemicals) in saline-tartaric acid/acetic acid plus
saline,

(d) SCH-23390 plus spiroperidol,

in saline-acetic acid,

(e) PLG (1.0 mg/kg)

(f) PLG + SCH-23390,(g)PLG+

spiroperidol, or (h) PLG + SCH-23390 + spiroperidol.

Rats

were weaned at 4 weeks and decapitated at 5, 8, or 12 weeks
of age.

At 12 weeks of age, groups of animals were treated

again, once a day for 17 consecutive days.

Rats that had

been treated neonatally with saline plus saline-tartaric
acid/acetic acid or with SCH-23390, or with spiroperidol or
with the combination of SCH-23390 plus spiroperidol received
the identical treatment at 12 weeks of age.

For rats treated

as adults, an interval of three days elapsed between the last
treatment and the time of decapitation to allow time for
elimination of drugs from striatal tissue. After
decapitation, brains were immediately removed and the striata
were dissected free, frozen on dry ice, and stored at-60° c.
Tissue Preparation:
At the time of assay striata were placed in 30 volumes
of 50 mM Tris buffer (pH 7.4) containing 120 mM NaCl, 5 mM

KCl, 1 mM MgCl2 , 10 uM pargyline, 0.1% ascorbic acid and 1 uM
ketanserin, the serotonin S2 receptor antagonist (Janssen
Pharmaceutical Co., Beerse, Belgium).

After homogenization

(setting of 50, 20 s; Tekmar Tissumizer) tissue suspensions
were incubated at 37° C for 30 minutes, in order to allow
dissociaton of any drug residue from the tissue. Samples were
centrifuged at 4B,OOOg for 25 min at 10° C in a Beckman
*

L5-75B ultracentrifuge.

This step was repeated after

resuspending the pellets in 30 volumes of fresh buffer.

The

final pellets were resuspended in the Tris-salt solution.
Binding Assay;
To assess total dopamine
of Schulz et al.

receptor binding, the method

(1985) was employed.

Briefly, samples of

0.2 ml of homogenate were added to [3H]SCH-23390

(300 pM,

final conc.; Amersham) in Tris-salt solution containing 2 mM
CaCl2 .

Samples (l ml incubation mix) were incubated for 15

min at 37° C in a shaking water bath, and then rapidly
filtered under partial vacuum on Whatman GF/F glass fiber
filters using a Millipore filtration unit.

Filters were

washed three times with ice-cold Tris-salt solution.

After

drying, filters were placed in 10 ml of Scintiverse E (Fisher
Scientific), and tritium activity was determined in a Beckman
LS 9800 liquid scintillation spectrometer.

Specific binding

of [3H] SCH-23390 was defined as the difference in binding in
the presence and absence of SCH-23390

(1 u M ) .
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D5 Binding Assay:
To assess total dopamine D2 receptor binding the method
of Creese and Snyder (1979) was used.

Aliquots of homogenate

(0,2 ml) were incubated with [3H] spiroperidol (300 pM, final
conc.; Amersham) in Tris-salt solution (1 ml incubation mix)
for 15 min at 37° C, and then rapidly filtered on Whatman
GF/F glass fiber filters.

Specific binding of [3H]

spiroperidol represented the difference in binding in the
presence and absence of d-butaclamol (1 uM; Research
Biochemicals, Inc.).
Kinetics Studies:
In order to determine the Bmax and Kp values for [3H]
SCH-23390 and [3H] spiroperidol receptor binding, Scatchard
analysis was used on the binding data from striatal
homogenates of 5 week old rats.
For [3H] SCH-23390 kinetic studies in rat striata, which
reflect dopamine

binding, rats were treated for 32 days

from day of birth with (a) saline,
i.p),

(b) SCH-23390 (0.3 mg/kg

(c) PLG (1.0 mg/kg or (d) SCH-23390 + PLG. The [3H]

SCH-23390 concentrations ranged from 50 to 1500 pM (8
concentrations, total). For [3H] spiroperidol kinetic studies
in rat striata, which reflect dopamine D2 binding, rats were
treated for 32 days from day of birth with (a) saline,
spiroperiodol (1.0 mg/kg i.p),

(b)

(c) PLG (1.0 mg/kg i.p), or

(d) spiroperidol + PIX3. The [3H] Spiroperidol concentrations
ranged from 50 to 1500 pM (8 concentrations, total).

Data Analysis
In the developmental study an analysis of variance
(ANOVA) followed by a post-ANOVA Newman-Keuls test was used
to analyze the data and to test for significant differences
between the treatment groups.

To test for the ability of

receptor antagonists to produce an upregulation of dopamine
Dj and D2 receptors an ANOVA was also used. A p value of
<0.05 was considered to be the level for statistical
significance.

Chapter III
Results

1.

Ontogenic Impairment of striatal

Receptors by Neonatal

SCH-23390!
Administration of the dopamine

receptor antagonist,

SCH-23390 (0.30 mg/kg, i.p.) to rats, once a day for 32
successive days from birth, resulted in a marked impairment
of striatal dopamine Di receptors at 5, 8 and 12 weeks
(p<0.001)

(figs. 1, 2, and 3).

In the group of rats treated

chronically with SCH-23390, total in vitro binding of
[^H]SCH-23390 to striatal homogenates was reduced by about
75% at all time intervals.

Groups treated with the

combination of SCH-23390 and spiroperidol (1 mg/kg i.p.)
exhibited the same degree of impairment of dopamine D]_
receptors binding as those treated with SCH-23390 alone,
indicating that dopamine D 2 receptor antagonism in
development does not permanently modify the ontogenic
impairment of dopamine

receptors by SCH-23390.

Also,

chronic spiroperidol treatment alone during ontogeny did not
alter the development of striatal dopamine
assessed at 8 and 12 weeks (figs. 2 and 3).
spiroperidol altered dopamine
(fig. 1).
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receptors, as
However,

receptor by 20% at 5 weeks
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Figure l. Total [3H]SCH-23390 binding to striatal
homogenates of 5 week old rats, chronically treated
postnatally with SCH-23390 and/or spiroperidol.
Animals were
treated i.p. once each day for 32 consecutive days from birth
with saline, spiroperidol (1.0 mg/kg), SCH-23390 (0.30
mg/Kg), or spiroperidol plus SCH-23390.
Each column represents the mean (+ S.E.H.) specific binding
of [3H]SCH“23390 (300 pM; pmol/g tissue), Values represent
data from 4 animals per group.
+, significantly different from the saline control group,
p<0.05; *, p <0.001, compared to the saline control group.
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Figure 2. Total [3H]SCH - 2 3 3 9 0 binding to striatal
homogenates of 8 week old rats, chronically treated
postnatally with SCH-23390 and/or spiroperidol. Animals were
treated i.p. once each day for 32 consecutive days from birth
with saline, spiroperidol {1.0 mg/kg), SCH-23390 (0.30
mg/kg), or spiroperidol plus SCH-23390.
Each column
represents mean (+ S.E.M.) specific binding of [3H]SCH-23390
(300 pM; pmol/g tissue) to striatal homogenates derived from
rats at 8 weeks from birth.
*,Statistically different from the saline control group
(p

<0.001).
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Figure 3. Total [3H]SCH-23390 binding to striatal
homogenates of 12 week old rats, chronically treated
postnatally with SCH-23390 and/or spiroperidol.
Animals were
treated i.p. once each day for 32 consecutive days from birth
with saline, spiroperidol (1.0 mg/kg), SCH-23390 (0.30
mg/kg), or spiroperidol plus SCH-23390. Each column
represents mean (+ S.E.M.) specific binding of [3H]SCH-23390
(300 pM; pmol/g tissue).
Control group represents [3H] SCH-23390 binding of
12.5 ±0.8 pmol/g tissue.Values represent data from 4 animals
per group.
*, statistically different from the saline control group
(p < 0 .0 0 1 ).
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2.

Ontocrenlc Impairment of Striatal Dopamine P2 Receptors bv

Neonatal Spiroperidol:
When the dopamine D2 receptor antagonist, spiroperidol
(1.0 mg/kg i.p.), was administered to rats once daily for 32
consecutive days from birth, there was a marked impairment of
the development of striatal dopamine D2 receptors at 5, 8 and
12 weeks (p<0.001)

(figs. 4,5 and 6).

Chronic spiroperidol

*

alone reduced total [3H] spiroperidol binding to striatal
membranes by 74%, 51% and 70%, at 5, 8, and 12 weeks,
respectively.

This effect was not modified in the group of

rats treated with spiroperidol and SCH-23390, indicating that
dopamine D2 receptor antagonism during development does not
modify the ontogenic impairment of dopamine D2 receptors by
spiroperidol.

Similarly, chronic SCH-23390 treatment alone

during ontogeny did not alter the development of striatal
dopamine D2 receptors at 8 weeks.

However, SCH-23390 altered

dopamine D2 receptors by 20% at 5 weeks (fig. 4).
3.

Dopamine
Dopamine

Receptor Kinetic Studies:
receptor kinetic studies were performed on

striatal tissue from 5 week old rats treated chronically with
saline, SCH-23390, PLG, and SCH-23390 + PLG, respectively. It
was found that treatments with SCH-23390 and/or PLG did not
alter the

from the control (K^ of saline group, 348.6+9.1

pM; mean and S.E.M).
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Figure 4. Total [3H]spiroperidol binding to striatal
homogenates of 5 week old rats, chronically treated with
spiroperidol and/or spiroperidol + SCH-23390.
Animals were
treated i.p. each day for 32 consecutive days with saline,
spiroperidol (1.0 mg/kg), SCH-23390 (0.3 mg/kg), or
spiroperidol plus SCH-23390. Each column represents mean
(+S.E.M.) specific binding of [3H]spiroperidol (300 pM;
pmol/g tissue).
Values represent data from 4 animals per group.
+, significantly different from the saline control group,
p <0.05;
*, p <0.001, compared to the saline control group.
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Figure 5. Total [3H]spiroperidol binding to striatal
homogenates of 8 week old rats, chronically treated with
spiroperidol and/or spiroperidol + SCH-23390. Animals were
treated i.p. each day for 32 consecutive days with saline,
spiroperidol (1.0 mg/kg), SCH-23390 (0.3 mg/kg), or
spiroperiodol plus SCH-23390. Each column represents the mean
(+ S.E.M.) specific binding of [3H] spiroperidol (300 pM;
pmol/g tissue}. Values represent data from 4 animals per
group.
*, p <0.001, compared to the saline group.
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Figure 6. Total [3H]spiroperidol binding to striatal
homogenates of 12 week old rats, chronically treated with
spiroperidol and/or spiroperidol + SCH-23390. Animals were
treated i.p. each day for 32 consecutive days with saline,
spiroperidol (1.0 mg/kg), SCH-23390 (0.3 mg/kg), or
spiroperidol plus SCH-23390. Each column represents the mean
(+ s.E.M.) specific binding of [3H] spiroperidol (300 pH;
pmol/g tissue).
Control group represents [3H] spiroperidol binding of 19+0.8
pmol/g tissue.
Values represent data from 4 animals per group.
*, p <0.001, compared to the saline control group.
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However, SCH-23390 treatment effectively reduced the Bmax by
78% from control (Bmax of saline group, 55.0+0.6 fmo1/mg
tissue) as shown in table 1 and figure 7*
4.

Dopamine Do Receptor Kinetic Studies:
Dopamine D % receptor kinetic studies were performed on 5

week old rats treated chronically with saline, spiroperidol,
PLG, and spiroperidol + PLG, respectively. It was found that
m

treatments with spiroperidol and/or PLG did not alter the KD
from the control (Kj) of saline group, 168+4.3 pM; mean and
5.E.M.). However, spiroperidol treatment effetively reduced
the Bmax by 75% from control (Bmax of saline group, 24.6+0.8
fmol/mg tissue) as shown in table 2 and figure 8.
5. PLG Attenuation of Receptor Impairment:
In groups of rats that were co-treated with the
neuropeptide PLG (1 mg/kg ip., for 32 days from day of
birth), there was complete attenuation of the effects of
chronic treatments with the dopamine D^ and D 2 receptor
antagonists*
In rats decapitated at 5 weeks (table 1) and at 8 weeks
(fig. 2), the total in vitro binding of dopamine D^ receptors
was similar in the saline control and PLG + SCH-23390-treated
groups. These results demonstrate the ability of PLG to
prevent the ontogenically impaired development of dopamine D^
receptors by chronic postnatal SCH-23390 treatment. Also, PLG
treatment for 32 days from birth, along with spiroperidol
(1 mg/kg i.p.), resulted in normal complement of striatal
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Figure 7. Scatchard analysis derived from [3H]SCH-23390
binding data of striatum of 5 week old rats. Each treatment
group represents the mean binding of 3 animals treated for
32 days postnatally with saline (i\), PLG
, l mg/kg ) , SCH
( ■ 0.3 mg/kg), or PLG + SCH-23390 ( Q , 1 mg/kg).
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Table 1.

Effect of 32 day postnatal treatments on rat striatal
dopamine D1 receptors+ , as determined by Scatchard analysis
of [H] SCH-23390 binding data.

Treatment

Saline
PLG (1.0 rag/kg/d)
SCH-23390 (0.30 mg/kg/d)
PLG + SCH-23390

Bmax
(fmol/mg tissue)
54.9
56.6
12.3
54.5

±
+
±
±

0.6
2.2
0.6*
1.8

kd

(pM)
348.6
334.0
328.0
339.0

+
4*
+
+

9.1
4.8
5.3
3.8

+ Each value is the + S.E.M. of 3 tissues.
* Indicates a significant difference from the saline control
group, p <0.001.
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Fig. B. Scatchard analysis derived from [3H] spiroperidol
binding data of striatum of 5 week old rats.
Each treatment
groups represent the mean binding of 3 animals treated for 32
days postnatally with saline ( A ) , PLG ^
, 1 mg/kg),
spiroperidol
,1 mg/kg), or PLG + spiroperidol
,
1 mg/kg).
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Table 2.

Effect of 32 day postnatal treatments on rat striatal
dopamine D2 receptor*, as determined by Scatchard analysis of
[3H] spiroperidol binding data.

Treatment

Saline
PLG (1.0 mg/kg/d)
Spiroperidol (1.0 mg/kg/d)
PLG + Spiroperidol

Bmax
(fmol/mg tissue)

24.6
23.9
6.3
23.6

±
+
±
+

0.8
0.4
0.2*
0.6

kd

(pM)

168.0
159.0
181.7
162.0

+ Each value is the mean + S.E.M. of 3 tissues.
* Indicates a significant difference from the saline
group, p <0.001.

+
±
±
+

4.3
4.9
3.2
4.5

control
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dopamine D2 receptors at 5 weeks (table 2) and at 8 weeks
(fig. 8).

These results also demonstrate the ability of PLG

to prevent the ontogenic impairment (decrease in number) of
dopamine D2 receptors when chronically blocked with a
specific antagonist (i.e. spiroperidol).
In conclusion, PLG is able to maintain a normal development
of dopamine receptors when these receptors are challenged
9

with chronic specific antagonist treatment.
6. Up-Reaulation of Ontoaenlcallv Impaired Striatal Dopamine
Dj Receptors After Chronic SCH-23390 Challenge of Adult Ra t s ;
In order to determine whether groups of rats with
ontogenically impaired striatal dopamine
respond to adult challenge with a dopamine
antagonist by up-regulating

receptors could
receptor

receptors, rats at 12 weeks of

age were given SCH-23390 (0.30 mg/kg i.p.) once a day for 17
successive days.

After a three day drug-free period, rats

were decapitated and total in vitro binding of [3H] SCH-23390
to striatal membranes was assessed.

It was found that when

ontogenically impaired rats were treated for 17 days with
»

*

SCH-23390, an up-regulation of dopamine
(pco.ool)

(fig. 9) resulted.

In the group

receptors
of rats treated

during postnatal ontogeny with SCH-23390, total [3H]
SCH-23390 in vitro binding to striatal membranes was reduced
by 74% at 12 weeks (fig. 3).

However, when SCH-23390 was

administered for 17 days in these mature rats, the result was
a three-fold increase in [3H] SCH-23390 binding, to 75% of

saline control levels. When spiroperidol was administered
alone (1.0 mg/kg i.p.), for 17 consecutive days in mature
rats, an up-regulation of dopamine
result.

receptors did not

Furthermore, when spiroperidol was administered in

conjunction with SCH-23390 to 12 week old rats for 17 days,
the response was the same as after treatment with SCH-23390
alone.

Thus, dopamine

receptor antagonism in mature rats

V

results in an up-regulation of striatal dopamine Dj receptors
even when this population of receptors is developmentally
reduced in number.

Challenge of these dopamine D]_

receptor-impaired adult rats with a dopamine D2 receptor
antagonist did not modify

receptor binding.

7. Lack of Up-Reoulatlon of Ontogenically Impaired Striatal
Do Receptors After Chronic Spiroperidol Challenge of Adult
Rats:
A 17 day treatment with spiroperidol (1.0 mg/kg/d i.p.)
in 12 week old rats with ontogenically impaired development
of striatal dopamine D2 receptors failed to change in vitro
binding of [3H] spiroperidol to striatal membranes at 12
weeks (fig. 10).

Also, when SCH-23390 was administered to

mature rats, alone or in combination with spiroperidol, the
binding of [3H] spiroderidol was not enhanced.
In groups of rats treated during postnatal ontogeny with
spiroperidol,

[3H] spiroperidol in vitro binding of dopamine

Dj> receptors was reduced by 70% at 12 weeks (fig. 6) ,
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Figure 9. Total [■1H]SCII*‘23390 binding to striatal homogenate
of 12 week old rats. Animals were chronically treated with
SCH-23390 as neonates, and again as adults. Neonatal rats
were treated once each day for 32 consecutive days from birth
with diluent or SCH-23390 (0.30 mg/kg i.p.).
At 12 weeks
after birth the diluent group received an additional 17 daily
treatments with diluent, while the SCH-23390 group received
an additional 17 daily treatments with SCH-23390.
Each column represents the mean (+S.E.M.) specific binding of
[3H] SCH-23390 (300pM? pmol/g tissue).
Control group represents [3H] SCH-23390 binding of 1 4 + 0 . 3
pmol/g tissue.
*, p <0.001, compared to the saline control group.
+, p <0.001, compared to the saline control group and SCH23390-treated group.
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Failure ot Striatal Dopamine D2 Receptors
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Fig. 10. Total [3H]spiroperiodol binding to striatal
homogenates of 12 week old rats. Animals were chronically
treated with spiroperidol as neonates and again as adults.
Neonatal rats were treated once each day for 32 consecutive
days from birth with diluent or spiroperidol (1.0 mg/kg
i.p.).
At 12 weeks after birth, the diluent group received
an additional 17 daily treatments with diluent, while the
spiroperidol group received an additional 17 daily treatments
with spiroperidol (1.0 mg/kg i.p.). Each column represents
the mean (+S.E.M.)- specific binding of [3H] spiroperidol (300
pM; pmol/g tissue).
Control group represents [3H] spiroperidol binding of
13 + 0.26 pmol/g tissue.
*, p <0.001, compared to the saline control group.

Chapter IV
Discussion

1.

Ontogenic Impairment of Dopamine

and Do Receptors:

The present study has shown that chronic postnatal
treatment of rats with highly selective dopamine

or D 2

antagonists results in a persistent impairment of striatal
dopamine

and D2 receptor ontogeny, respectively, as

measured at 5, 8, and 12 weeks by total in vitro binding
assays.

At 5 weeks only, SCH-23390-treatment resulted in a

20% decrease in total [3H] spiroperidol binding to striatum,
while spiroperidol treatment resulted in a 20% decrease in
total [3H] SCH-23390 binding. This finding

demonstrates that

the postnatal period is sensitive and critical for normal
development of striatal dopamine Dj_ and D2 receptors, and
that the chronic blockade of dopamine receptors during this
period may lead to permanent impairment in the ontogeny of
the receptors.
The impairment in dopamine receptor ontogeny is
reflected by the decrease in the total specific binding
measured by in vitro assays or, simply a decrease in the
number of dopamine receptors.

At the time that dopamine D2

receptors are ontogenically impaired, the dopamine
receptor binding is normal and vice versa.

This suggests a

functional impairment in the dopamine system, not an
anatomical one. In rat striatum there is evidence that
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dopaminergic innervation is incomplete at the time of
maturation of striatal dopamine D 2 receptors,

receptors,

and dopamine-stimulated adenylate cyclase (Giorgi et al.,
1987; Pardo et. al., 1977).

The density of the dopamine Di

receptors increased rapidly from 9% of the adult level at
birth, to a peak value by postnatal day 35 (Giorgi et al.,
1987).

The dopamine content at birth is 12% of the adult

level and increase slowly until reaching adult level by
postnatal day 60. The dopamine content is an indication of
dopaminergic innervation and presynaptic terminal maturation.
Therefore, it can be suggested that the postnatal period is a
critical period with regard to dopaminergic development, and
antagonistic treatment during this period may alter this
development, mainly through postsynaptic receptor sites.

The

impairment in dopamine receptor ontogeny is apparently due to
impairment in the ability of the dopamine receptor cells to
express a normal number of dopamine receptors after chronic
blockade.

Also, specific chronic blockade of dopamine

receptors may interfere with signals that are transmitted to
*

the cell nuclei to stimulate greater expression of dopamine
receptors (up-regulation). An increase in the number of
striatal O 2 receptors was observed when haloperidol was
administered to rats for the first three weeks from birth
(Kosengarten and Friedhoff, 1979) or when adult rats were
chronically treated with haloperidol (Chiu et al., 1981).
The same up-regulatory response was observed when dopamine
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receptors were chronically blocked by SCH-23390 in adult rats
(Creese and Chen, 1985),
In the prenatal study by Rosengarten and Friedhoff
(1979) dopamine D2 ontogeny was permanently impaired
following haloperidol treatment during a 3-day critical
period (15-18 days of gestation).

In their postnatal study

dopamine D2 receptor up-regulation was reported following
haloperidol treatment for 3 weeks from birth.

There are

several differences between the present study and the earlier
postnatal study.
In the earlier study, the amount of haloperidol received
by each pup in the milk could not be easily quantified, and
as the pups approached 21 days of age, any consumption of
pelleted food may have reduced milk and drug consumption.
Also, haloperidol may have affected the hormonal system in
the lactating dams, by blocking D2 receptors in the pituitary
gland, which increases prolactin release and may further
dilute the drug in the milk.

In the earlier report,

serotonin S2 receptors were not inactivated in the in vitro
procedure for [3H] spiroperidol binding, so that serotonin S2
receptor changes may have artifactually altered results.
This does not exclude the possibility of serotonin S2 sites
proliferating as a result of haloperidol treatment, which
would make the binding assay results non-specific for
dopamine D2 receptors.

In the present study, spiroperidol, a

more specific dopamine D2 receptor antagonist was used, with

the dose kept constant during the treatment period.

Xn

addition, ketanserin, a serotonin S 2 receptor antagonist
(Leyson et al., 1981) was employed in the in vitro binding
assay.

Also, in this study neonates were treated daily for

32 days, not only for 21 days; the period between 21 and 32
days could be critical for the development of dopamine
receptors.

It is suggested that the continuous treatment for

32 days may be needed in order to accumulate enough changes
that persistent impairment in dopamine receptor ontogeny can
be observed.
Regarding the ability of dopamine D 2 antagonists to
alter dopamine

receptor ontogeny by 20% at 5 weeks, it can

be suggested that the chronic blockade of dopamine D 2
receptors in the postnatal period is able to impair normal
expression of dopamine

receptors.

impairment is transient, and dopamine

However, this
receptors regain

development to normal levels after treatment with dopamine D2
antagonists is terminated.
to the way dopamine

The same reasoning may be applied

antagonists affect dopamine D 2

*

receptors.
In conclusion, the present findings demonstrate that the
process of striatal dopamine

and D2 receptor development

can be substantially impaired by chronic antagonist treatment
in the postnatal period.

It is not known at this time

whether there is a specific period during postnatal
development when the receptors are particularly susceptible
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to antagonists. Additional studies are needed to define the
mechanisms that are associated with the altered ontogeny of
dopamine receptors.
2.

PLG Attenuation of Dopamine Receptor Ontooenic

Impairment;
The ability of PLG to attenuate dopamine
ontogenic impairment is a new finding.

and D2

It has been reported

that PLG modulates the neuroleptic-induced up-regulation of
dopamine D 2 receptors in adult rats (Chiu et al., 1981;
Bhargava, 1984).

However, this neuroleptic-induced receptor

up-regulation is a relatively short-lived phenomenon, since
within 2 weeks after the termination of treatment, dopamine
receptor number is at control levels. In the present study, a
down-regulation of dopamine D2 receptors was effected.

This

change persisted for at least 3 to 4 months, and the reversal
or prevention of this persistent change in dopamine D2
receptor number by PLG is of great importance regarding
possible regulatory mechanisms associated with receptor
development.

It is also of great importance regarding their

ontogenic impairment during neurological dysfunction related
to the dopamine system.
In addition, the present study demonstrates that PLG is
able to attenuate the persistent ontogenic impairment of
striatal dopamine
SCH-23390.

receptors after chronic treatment with

These results highlight the involvement of PLG in
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modulating dopamine

and dopamine D2 receptor development

and ontogenic impairment.
It has been reported that, when added in combination
with apomorphine, PLG acutely lowers the K q

(an increase in

the affinity of the receptor to bind to the agonist)

for

in vitro binding of [3H] apomorphine to striatal homogenates
without affecting [3H] spiroperidol binding (Bhargava, 1983 &
1984; Chiu et al., 1981).

It is therefore suggested that PLG

may act in vitro to potentiate dopaminergic neurotransmission
by interacting with its own binding sites, which are located
in an area that allows them to influence dopamine receptor
activity.

It is also suggested that PLG is able to alter

neuronal gene expression and the de novo synthesis of new
dopamine receptor protein, since the short half-life of PLG
will not allow it to act on or compete for the dopamine
receptor sites and to have such a strong ability to modulate
dopamine receptor ontogeny.

PLG may act directly on the gene

that expresses dopamine receptors, in order to modulate any
abnormal changes in that expression.

It should also be

mentioned that dopamine neuronal activities are modulated by
the action of neurochemical systems (i.e. GABA, substance P,
enkephalin)

(Kelley et al., 1982), and a reduction in these

neurochemicals may lead to a profound motor behavior
dysfunction, i.e. Huntington's Disease (Emson et al., 1980).
The possibility needs to be considered that PLG may be
indirectly modulating dopamine receptors through an action on
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these other neurochemical systems.

It may he useful to

determine the action of chronic PLG treatment on the above
substances, under long-term blockade with dopamine

and D2

antagonists.
The present results demonstrate that the neuropeptide
PLG is able to attenuate the impaired ontogenic development
of striatal dopamine

and D2 receptors that is produced by

specific receptor antagonists.

Explanation of this

phenomenon should lead to a better understanding of dopamine
receptor regulation and related neuroreceptor dynamics.
These results reinforce the previous suggestion (Chiu et al.,
1980, 1981) for the clinical use of PLG to attenuate abnormal
dopamine receptor changes i.e. in Parkinson's disease,
anti-psychotic therapy, and drug addiction.
3.

The Ability of Dopamine

Receptors to Up-Reaulate in

Adults;
The present study has shown that the postnatal treatment
of rats for 32 days from birth with the dopamine

or D2

receptor antagonists results in persistent ontogenic
impairment of both
12 weeks of age.

and D2 dopamine receptors at 5, 8, and
The study has also shown that dopamine D2

receptors do not up-regulate (increase in number) when
rechallenged in adult rats (fig. 8),
dopamine

On the other hand,

receptors do up-regulate when rechallenged in

adult rats (fig. 7).
This up-regulation of ontogenically impaired striatal

dopamine

receptors after chronic treatment of adult rats

with sCH-23390 is analogous to the up-regulation of
unimpaired striatal dopamine Di receptors after SCH-23390
treatment of adult rats (Creese and Chen, 1985).

SCH-23390

chronic administration had no affect on striatal dopamine D2
receptors in either the ontogenically impaired or control
rats.
r

Failure of ontogenically impaired striatal dopamine D 2
receptors to up-regulate in response to challenge of adult
rats with spiroperidol contrasts with the up-regulation of
these receptors in intact control rats challenged as adults
with neuroleptics (Seeman, 1980).

It is possible that a

higher dose of spiroperidol can stimulate dopamine D2
up-regulation; however, the challenge doses of receptor
antagonists are moderate and identical to the dose of
antagonist that was administered during development.
in this study, both dopamine

Also,

and D2 receptor binding was

ontogenically impaired to the same degree, prior to adult
challenge with a receptor antagonist.
up-regulation of dopamine

The differential

receptors may reflect

differences in the ability of the dopamine

and D2

receptors to respond to receptor antagonism.

The adenylate

cyclase system that is directly stimulated by dopamine
receptors (Kababian and Caine, 1979) may have the ability to
recover some of the normal response of dopamine D]_ receptors
(up-regulation) upon challenging treatment.

On the other

hand there is either no relationship or a negative
relationship between dopamine D£ receptors and the adenylate
cyclase system,* dopamine D 2 receptors did not up-regulate.
Also there is evidence that dopamine D 2 receptors are
modulated by the guanine nucleotide system (Grigoriadis and
Seeman, 1985), which may have a different response to
challenging treatment from that of the adenylate cyclase
system regarding impaired striatal dopamine receptors.
In conclusion, ontogenically impaired dopamine

and D 2

receptors showed different responses to challenging
treatment, in which dopamine

receptors up-regulated and

dopamine D 2 receptors did not, following treatment with
specific antagonists as adults.

This may be of importance

with regards to the etiology and management of psychiatric
disorders related to the dopaminergic system.

Chapter V
Summary

Chronic postnatal treatment of rats with SCH-23390 or
spiroperidol, selective dopamine D]_ or D 2 receptor
antagonists, causes permanent impairment in the development
V

of the respective striatal receptors.

This developmental

impairment is reflected by a decrease in the specific binding
of [3H] SCH-23390 and [3H] spiroperidol, respectively, to
striatal homogenates as assessed at 5, 8 and 12 weeks.

As

indicated at 5 weeks, the decrease in [3H] SCH-23390 and [3H]
spiroperidol binding is associated with a decrease in the
Bmax for the dopamine

and D 2 receptors, respectively.

Since the K q is unchanged, the ontogenic impairment is
reflective of a change in number, not the affinity of the
dopamine

and D 2 receptor types.

These results indicate

that the postnatal period is a sensitive and critical one for
normal expression of striatal dopamine receptors.
*

The

*

neuropeptide PLG was able to totally attenuate the ontogenic
impairment of striatal dopamine

and D2 receptors that was

caused by chronic postnatal treatment with selective dopamine
and D 2 antagonists.

These results also indicate that PLG

is capable of modulating abnormal developmental changes in
striatal dopamine

and D 2 receptors.
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